These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16269190)

  • 41. Inverse agonism or neutral antagonism at G-protein coupled receptors: a medicinal chemistry challenge worth pursuing?
    Greasley PJ; Clapham JC
    Eur J Pharmacol; 2006 Dec; 553(1-3):1-9. PubMed ID: 17081515
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.
    Goodacre CJ; Bromidge SM; Clapham D; King FD; Lovell PJ; Allen M; Campbell LP; Holland V; Riley GJ; Starr KR; Trail BK; Wood MD
    Bioorg Med Chem Lett; 2005 Nov; 15(22):4989-93. PubMed ID: 16168649
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.
    Heal DJ; Smith SL; Fisas A; Codony X; Buschmann H
    Pharmacol Ther; 2008 Feb; 117(2):207-31. PubMed ID: 18068807
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of contractile 5-hydroxytryptamine receptor subtypes in the in situ autoperfused kidney in the anaesthetized rat.
    Morán A; Ortiz de Urbina AV; Martín ML; García M; Rodriguez-Barbero A; Dorado F; San Román L
    Eur J Pharmacol; 2008 Sep; 592(1-3):133-7. PubMed ID: 18644367
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors.
    Blaazer AR; Smid P; Kruse CG
    ChemMedChem; 2008 Sep; 3(9):1299-309. PubMed ID: 18666267
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A conservative, single-amino acid substitution in the second cytoplasmic domain of the human Serotonin2C receptor alters both ligand-dependent and -independent receptor signaling.
    Berg KA; Dunlop J; Sanchez T; Silva M; Clarke WP
    J Pharmacol Exp Ther; 2008 Mar; 324(3):1084-92. PubMed ID: 18065501
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction.
    Chanrion B; Mannoury la Cour C; Gavarini S; Seimandi M; Vincent L; Pujol JF; Bockaert J; Marin P; Millan MJ
    Mol Pharmacol; 2008 Mar; 73(3):748-57. PubMed ID: 18083778
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Theoretical models of interactions between buspirone analogues and 5-HT1A and 5-HT2A serotonin receptor subtypes.
    Bronowska A; Sylte I; Edvardsen Ø; Østensen R; Leś A; Chilmonczyk Z
    Acta Pol Pharm; 2000 Nov; 57 Suppl():40-5. PubMed ID: 11293260
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases.
    Wacker DA; Miller KJ
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):438-45. PubMed ID: 18600561
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 5-HT2c receptor activation induces grooming behaviour in rats: possible correlations with obsessive-compulsive disorder.
    Gráf M
    Neuropsychopharmacol Hung; 2006 Mar; 8(1):23-8. PubMed ID: 16841562
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A receptors.
    Görnemann T; Hübner H; Gmeiner P; Horowski R; Latté KP; Flieger M; Pertz HH
    J Pharmacol Exp Ther; 2008 Mar; 324(3):1136-45. PubMed ID: 18096760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists for the treatment of sleep disorders.
    Ladduwahetty T; Gilligan M; Humphries A; Merchant KJ; Fish R; McAlister G; Ivarsson M; Dominguez M; O'Connor D; MacLeod AM
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3708-12. PubMed ID: 20493697
    [TBL] [Abstract][Full Text] [Related]  

  • 53. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology.
    Adams JW; Ramirez J; Shi Y; Thomsen W; Frazer J; Morgan M; Edwards JE; Chen W; Teegarden BR; Xiong Y; Al-Shamma H; Behan DP; Connolly DT
    J Pharmacol Exp Ther; 2009 Oct; 331(1):96-103. PubMed ID: 19628629
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems.
    Stachowicz K; Kłodzińska A; Palucha-Poniewiera A; Schann S; Neuville P; Pilc A
    Neuropharmacology; 2009 Sep; 57(3):227-34. PubMed ID: 19539634
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The nociceptive mechanism of 5-hydroxytryptamine released into the peripheral tissue in acute inflammatory pain in rats.
    Nakajima K; Obata H; Ito N; Goto F; Saito S
    Eur J Pain; 2009 May; 13(5):441-7. PubMed ID: 18656400
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Psychosis of Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeutics.
    Weiner DM; Vanover KE; Brann MR; Meltzer HY; Davis RE
    Curr Opin Investig Drugs; 2003 Jul; 4(7):815-9. PubMed ID: 14619402
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder.
    Bös M; Jenck F; Martin JR; Moreau JL; Sleight AJ; Wichmann J; Widmer U
    J Med Chem; 1997 Aug; 40(17):2762-9. PubMed ID: 9276022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protean agonism at histamine H3 receptors in vitro and in vivo.
    Gbahou F; Rouleau A; Morisset S; Parmentier R; Crochet S; Lin JS; Ligneau X; Tardivel-Lacombe J; Stark H; Schunack W; Ganellin CR; Schwartz JC; Arrang JM
    Proc Natl Acad Sci U S A; 2003 Sep; 100(19):11086-91. PubMed ID: 12960366
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In the search for selective ligands of 5-HT5, 5-HT6 and 5-HT7 serotonin receptors.
    Wesołowska A
    Pol J Pharmacol; 2002; 54(4):327-41. PubMed ID: 12523486
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 5-HT2A antagonists in psychiatric disorders.
    de Angelis L
    Curr Opin Investig Drugs; 2002 Jan; 3(1):106-12. PubMed ID: 12054060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.